Eisai Files Application for A New Indication for PARIET (rabeprazole sodium) in Japan for H. Pylori Eradication Indication
Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announces today that the company has filed an application for a new indication of PARIET (generic name: rabeprazole sodium), a proton pump inhibitor, for H. pylori eradication in combination with amoxycillin and clarithromycin in Japan.
H. pylori is a type of bacteria that exists in stomach of human and known to be involved in the pathology of peptic ulcer development. By the filing for new indication, Eisai expects to contribute to the prevention of peptic ulcer reoccurrence.
PARIET was first launched in Japan in 1997, in Europe in 1998, and as ACIPHEX in the U.S. in 1999. It is marketed in 72 countries worldwide. In the U.S and Europe, PARIET has already been approved for H. pylori eradication in combination with amoxycillin and clarithromycin.
Since its establishment, Eisai has been committed to developing drugs for the treatment of gastrointestinal diseases. The company hopes to contribute further to the treatment of acid-related diseases.
Eisai Co., Ltd.
Corporate Communications Department